Jingxin Wang received his B.S. in Chemistry from Peking University in 2006, where he conducted research in transition-metal catalysis under the mentorship of Professor Zhi-Xiang Yu. He completed his Ph.D. in Chemistry at the University of Maryland in 2011 under the guidance of Professor Herman Sintim, where he was trained in the design and synthesis of small molecules to combat bacterial antibiotic resistance. He then pursued postdoctoral research in Professor Jun Liu’s laboratory at Johns Hopkins University, where he contributed to the development of rapafucins, a class of non-degrading molecular glues designed to induce protein–protein interactions. In 2014, he continued his chemical biology training at The Scripps Research Institute and Calibr (the drug discovery division of Scripps Research) in the laboratory of Professor Peter Schultz (co-advised by Dr. Kristen Johnson). There, he focused on high-throughput screening, assay development, and target validation for antiviral and cancer immunotherapy programs, while also conducting mechanistic studies of small molecules that modulate RNA splicing. 

Dr. Wang began his independent career as a tenure-track Assistant Professor at the University of Kansas in 2019 and moved to the University of Chicago in 2024. His research program centers on small-molecule recognition of RNA and the chemical modulation of RNA splicing. His laboratory develops new chemical strategies to control RNA structure and function in cells, with a primary focus on neurodegenerative diseases, antiviral research, and cancer, and additional efforts directed toward understanding how RNA-targeting molecules intersect with innate immune pathways.